Skander Mulder

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Hiddo J.L. Heerspink, Paul Perco, Skander Mulder et al. · Diabetologia · 2019 · 453 citations · Full text

Medicine, Molecular Biology, Pharmacology +17

Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes

Bauke Schievink, Tobias F. Kröpelin, Skander Mulder et al. · Diabetes Obesity and Metabolism · 2015 · 72 citations

Medicine, Internal Medicine, Nephrology +17

Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes

Skander Mulder, Hiddo J.L. Heerspink, Manjula Darshi et al. · Diabetes Obesity and Metabolism · 2019 · 64 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

Skander Mulder, Ann Hammarstedt, Sunil B. Nagaraj et al. · Diabetes Obesity and Metabolism · 2020 · 57 citations · Full text

Medicine, Nephrology, Pharmacology +17

Dynamic Digital Twin: Diagnosis, Treatment, Prediction, and Prevention of Disease During the Life Course

Skander Mulder, Amir‐Houshang Omidvari, Anja J. Rueten‐Budde et al. · Journal of Medical Internet Research · 2022 · 55 citations · Full text

Computing, Health Care Management, Health Informatics +13